A 28-year-old woman with a 5-year history of asthma presents to the pulmonology clinic with worsening symptoms. Spirometry shows FEV1 of 52% predicted, FEV1/FVC ratio of 0.62, and a concave expiratory flow-volume curve. She reports continuous daytime symptoms, nightly awakening due to breathlessness, and uses her rescue inhaler 4–5 times daily. Physical activity is severely limited. Her asthma severity classification corresponds to the category marked **D** in the diagram. Which of the following GINA treatment steps is most appropriate as initial controller therapy for this severity category?

Question

Accepted Answer

B. Step 5: High-dose ICS-LABA plus add-on therapy (LAMA, biologic, or both). ## Why Step 5: High-dose ICS-LABA plus add-on therapy is right The patient's clinical presentation—FEV1 <60% predicted, continuous daytime symptoms, nightly awakenings, multiple-times-daily reliever use, and extreme activity limitation—defines SEVERE PERSISTENT asthma (category **D**). According to GINA 2024, Step 5 is the appropriate initial controller regimen for severe persistent asthma. This step mandates high-dose ICS-LABA as the backbone, with mandatory add-on therapy: either a LAMA (long-acting muscarinic antagonist such as tiotropium), or a biologic agent targeting type 2 inflammation (anti-IgE omalizumab, anti-IL-5 mepolizumab/reslizumab, anti-IL-5R benralizumab, anti-IL-4Rα dupilumab, or anti-TSLP tezepelumab), or both. This escalated approach reflects the severity of airflow obstruction and symptom burden, and the need for multi-modal anti-inflammatory control. ## Why each distractor is wrong - **Step 3: Low-dose ICS-LABA**: This is appropriate for moderate persistent asthma (FEV1 60–80%, daily symptoms, >1 weekly nighttime awakening). The patient's FEV1 <60% and continuous symptoms exceed this threshold. - **Step 4: Medium-dose ICS-LABA**: This is used for moderate-to-severe asthma that is not yet severe persistent. The patient's FEV1 <60%, nightly awakenings, and extreme activity limitation place her beyond Step 4. - **Step 2: Daily low-dose ICS or as-needed ICS-formoterol**: This is for mild persistent asthma (FEV1 >80%, symptoms >2/week but not daily). The patient's continuous symptoms and severely reduced FEV1 make this grossly inadequate. **High-Yield:** Severe persistent asthma (FEV1 <60%, continuous symptoms, nightly awakenings, extreme activity limitation) requires GINA Step 5: high-dose ICS-LABA + mandatory add-on therapy (LAMA or biologic). Severity classification guides stepwise pharmacotherapy escalation. [cite: GINA Global Strategy for Asthma 2024; Harrison's Principles of Internal Medicine 21e]

Answer

A. Step 3: Low-dose ICS-LABA maintenance therapy

Answer

C. Step 2: Daily low-dose ICS or as-needed ICS-formoterol

Answer

D. Step 4: Medium-dose ICS-LABA maintenance therapy

Explanation

Why Step 5: High-dose ICS-LABA plus add-on therapy is right

Why each distractor is wrong

Practice similar questions